Education
About Us
Working with TipRanks
Follow Us
Surrozen (SRZN)
NASDAQ:SRZN
SRZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.00 - $18.17
Previous CloseN/A
Volume12.23K
Average Volume (3M)13.07K
Market Cap
$84.95M
Enterprise Value$20.71M
Total Cash (Recent Filing)-$29.10M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.32
Next Earnings
May 07, 2025EPS Estimate
-2.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-21.27
Shares Outstanding8,494,584
10 Day Avg. Volume11,442
30 Day Avg. Volume13,075
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.05
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.76
Enterprise Value/Ebitda-0.82
Forecast
1Y Price Target
$32.00Price Target Upside220.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Surrozen News
PremiumCompany Announcements
Surrozen Focuses on Ophthalmology Amid Financial Challenges
PremiumCompany Announcements
Surrozen Secures $76.4M in Private Placement Deal
---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommendation is to initiate coverage with a Buy rating and $32 price target.
Industry ValidationThe recent validation of the Wnt pathway by major acquisitions in the industry, like Merck acquiring EyeBio and Roche acquiring AntlerA, supports the potential of the Wnt mechanism.
Strategic PartnershipsThe strategic partnership with Boehringer Ingelheim for developing candidate SZN-413 in retinal vascular-associated diseases provides important validation for Wnt modulation.
Bears Say
Dependency On PartnershipsThe collaboration and licensing agreement with Boehringer Ingelheim for bi-specific antibody SZN-413, targeting Fzd4-mediated Wnt signaling in retinopathies, provides upside beyond the internal Wnt pipeline for vascular pathology.
---
Ownership Overview
29.43% Insiders
0.97% Mutual Funds
17.58% Other Institutional Investors
51.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $6.00 and its highest was $18.17 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $84.95M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is May 07, 2025 which is in 11 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on Mar 31, 2025. The company reported -$9 earnings per share for the quarter, missing the consensus estimate of -$1.09 by -$7.91.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -2.71.
How many shares outstanding does Surrozen have?
Surrozen has 8,494,584 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$9 in its last earnings report, missing expectations of -$1.09. Following the earnings report the stock price went down -4.631%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
---
Surrozen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (220.00% Upside)
$32.00 (220.00% Upside)
Insider Transactions
Bought Shares
Worth $12.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.48%
12-Months-Change
Fundamentals
Return on Equity
-767.91%
Trailing 12-Months
Asset Growth
5.18%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
---
SRZN Stock 12 Month Forecast
Average Price Target
$32.00
▲(220.00% Upside)
Technical Analysis
Veru
―
MacroGenics
―
Whitehawk Therapeutics
―
Black Diamond Therapeutics
―
Aziyo Biologics
―
Best Analysts Covering SRZN
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-15.75%
reiterated a buy rating 25 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -15.75% per trade.
---